Dr Reddy's Prepares for Landmark Launch of Generic Semaglutide in India
Indian drugmaker Dr Reddy's Laboratories is set to launch its generic semaglutide injection under the brand name Obeda in March. This follows the upcoming expiration of patent protection for the compound in India, spurring a rush among drugmakers to introduce cost-effective versions of the diabetes and weight-loss drug.
Dr Reddy's Laboratories, a leading Indian drugmaker, plans to launch its generic version of semaglutide, named Obeda, by March, insiders have revealed.
The move aligns with the approaching expiration of semaglutide's patent in India, scheduled for March 2026, prompting a competitive drive among Indian pharmaceutical companies preparing to offer affordable alternatives. Semaglutide is a key component in Novo Nordisk's acclaimed diabetes medication Ozempic and its weight-loss counterpart, Wegovy.
With over 440 million individuals in India projected to be overweight or obese by 2050, Dr Reddy's anticipates selling 12 million units of its injectable semaglutide within a year, pricing it at potentially 60% less than the branded offering. Regulatory steps to produce and sell generic Ozempic have been cleared, while approval for a generic version of Wegovy is awaited.
ALSO READ
-
Boosting India's Veterinary Industry: Indigenous Hormone Production Takes Center Stage
-
US Imposes Hefty Duties on Indian Solar Imports
-
Global Capability Centres Drive Demand in India's Office Space Market
-
Rahul Gandhi poster boy of negative politics, compromised national interest by joining hands with anti-India forces:Piyush Goyal to reporters.
-
Empowering Exports: India's Thriving Smartphone Industry
Google News